Pregnancy blood clot risk: are current doses right?
NCT ID NCT01394107
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study checked how a standard dose of a blood thinner (LMWH) affects clotting in 40 pregnant women just before a planned C-section. The goal was to see if the dose is safe and effective for preventing dangerous blood clots, which are a leading cause of death in new mothers. Researchers used advanced tests to measure clotting over 24 hours and to assess the risk of spinal bleeding during anesthesia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Low molecular weight heparin (LMWH)
- What this could lead to
- If successful, this could help doctors determine the right blood-thinner dose for pregnant women, reducing clot risks without increasing bleeding danger.
- What could go wrong
- This is a small pilot study with only 40 participants, so results may not apply to all pregnant women. The findings are observational and need confirmation in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
General University Hospital in Prague
Prague, 128 08, Czechia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a class tame pregnancy stress at the genetic level?
- A nationwide test: do home visits build healthier families?
- Can a simple calcium tablet help prevent postpartum bleeding?
- Can AI read ultrasound sweeps to tell Baby's position?
- Could a smart ring unlock secrets of pregnancy health?
- Could Video-Led pelvic exercises redefine prenatal care?